여성 건강 시장 : 제품별, 용도별, 유통 채널별, 최종 사용자별, 연령층별 - 세계 시장 예측(2026-2032년)

The Women's Health Market is projected to grow by USD 98.78 billion at a CAGR of 8.66% by 2032.

Women's Health Market Introduction

Women's health is moving from a historically underfunded specialty into a strategic healthcare priority spanning reproductive health, maternal care, oncology, menopause, cardiovascular disease, autoimmune conditions, pelvic health, and mental health. The demand signal is clear: WHO estimates about 287,000 maternal deaths occurred in 2020, while IARC reported 2.3 million breast cancer cases and about 660,000 cervical cancer cases worldwide in 2022.

For providers and health systems, the opportunity is to close gaps across the full female life course. Evidence-backed care pathways, earlier screening, equitable access, and integrated digital services are becoming essential as women continue to experience higher rates of delayed diagnosis in conditions such as endometriosis, which WHO estimates affects about 190 million reproductive-age women globally.

Transformative Shifts in Women's Health

The women's health landscape is being reshaped by demographic aging, rising chronic disease burden, consumer demand for personalized care, and policy pressure to improve maternal and reproductive outcomes. Menopause, fertility, contraception, gynecologic oncology, pelvic floor disorders, and cardiometabolic health are shifting from fragmented services into longitudinal care models.

Healthcare delivery is also moving beyond episodic intervention. Remote monitoring, home diagnostics, hybrid fertility care, community-based maternal support, and culturally competent clinical pathways are improving reach. The strongest organizations are aligning women's health strategy with value-based care, prevention, and measurable outcomes rather than treating it as a narrow obstetrics and gynecology segment.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating women's health through risk prediction, imaging support, care navigation, patient stratification, and workflow automation. In breast imaging, cervical screening, fertility planning, and maternal risk monitoring, AI can help clinicians identify high-risk patients earlier when models are validated on representative populations and used with clear clinical governance.

The cumulative impact will depend on trust, data quality, and bias mitigation. Women, racial and ethnic minorities, and pregnant individuals have historically been underrepresented in clinical research, making inclusive datasets essential. AI should augment clinical judgment, improve triage, and reduce administrative burden while maintaining transparency, privacy, and regulatory compliance.

Key Regional Insights

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in fertility care, maternal health, digital platforms, and cancer screening, supported by high population needs and widening healthcare access. North America benefits from advanced specialty networks, high digital health adoption, and strong clinical research capacity, although maternal mortality and access disparities remain major priorities, particularly in the United States, where CDC data show maternal mortality remains above many peer high-income countries.

Latin America is gaining momentum through public vaccination, contraception access, and oncology programs, with Brazil and Mexico anchoring regional demand for reproductive health, cancer screening, and private-sector specialty care. Europe is advancing through structured breast and cervical cancer screening, reimbursement discipline, and regional health data initiatives. The Middle East is investing in women's specialty hospitals, fertility services, and preventive screening as part of national health transformation strategies, while Africa's greatest opportunity remains scalable maternal care, HPV vaccination, diagnostics, skilled birth attendance, and primary health access to reduce preventable morbidity and mortality.

Key Group Insights

ASEAN markets are prioritizing maternal health, reproductive services, HPV vaccination, and mobile-first care models as urbanization, rising health literacy, and digital adoption expand across Southeast Asia. The GCC is investing in premium hospitals, fertility centers, preventive screening, and women's wellness services aligned with national health transformation agendas, creating demand for high-quality specialist care and clinically governed digital health platforms.

The European Union supports women's health through coordinated cancer screening, data governance, reproductive health policy, and reimbursement frameworks, while BRICS countries represent high-volume needs in maternal care, affordable medicines, diagnostics, oncology access, and digital inclusion. G7 markets lead in research intensity, precision diagnostics, advanced therapeutics, and menopause and fertility innovation, and NATO countries show growing interest in resilient medical supply chains, health security, interoperable data infrastructure, and continuity of care for women in civilian and defense health systems.

Key Country Insights

The United States leads in specialty care innovation, clinical research, digital women's health, fertility services, and advanced oncology pathways, while Canada emphasizes universal access, maternal outcomes, breast and cervical cancer screening, and equitable care across provinces. Mexico and Brazil are expanding access through public programs and private networks, especially in contraception, fertility, maternal care, and oncology. The United Kingdom, Germany, France, Italy, and Spain are strengthening menopause care, screening, reproductive services, and chronic disease management under mature reimbursement and public health systems, while Russia remains driven by hospital-based care, public health priorities, reproductive services, and oncology needs.

China is scaling fertility services, maternal care, oncology screening, and digital health infrastructure; India is advancing maternal health, affordable diagnostics, HPV vaccination efforts, telehealth, and community-based care; Japan faces strong demand linked to aging, menopause-related needs, low fertility, and chronic disease prevention; Australia benefits from high screening participation, digital infrastructure, and strong primary care coordination; and South Korea combines advanced diagnostics, fertility services, high technology adoption, and preventive care models to support women across reproductive, midlife, and aging health needs.

Actionable Recommendations for Industry Leaders

Industry leaders should build full life-course women's health strategies that integrate prevention, diagnostics, therapeutics, behavioral health, and long-term follow-up. Priority investments should target maternal safety, endometriosis and PCOS pathways, menopause services, cardiovascular risk detection, gynecologic cancer screening, fertility care, contraception access, pelvic health, and equitable access for underserved populations.

Vendors should focus on interoperable data, clinically validated AI, outcomes-based partnerships, and patient-centered design. Organizations that combine evidence generation, regulatory readiness, inclusive clinical trials, privacy-by-design architecture, and culturally competent engagement will be better positioned to improve outcomes, strengthen trust, and capture sustainable growth without widening existing care disparities.

Research Methodology

This executive summary is based on secondary research from authoritative public sources, including WHO, IARC/GLOBOCAN, UNFPA, OECD, World Bank, national health agencies, peer-reviewed literature, and regulatory guidance. Insights were cross-checked against epidemiological indicators, care delivery trends, reimbursement patterns, screening guidance, maternal health metrics, and technology adoption signals.

The methodology emphasizes data triangulation, market segmentation, regional comparison, and qualitative validation of demand drivers. Findings are interpreted through a healthcare delivery lens to identify practical implications for providers, health systems, payers, innovators, policymakers, and public health stakeholders while avoiding unverified estimates, market sizing, market share claims, or forecasting.

Conclusion

Women's health is entering a new growth phase defined by prevention, personalization, equity, and digital transformation. The strongest opportunities will come from addressing high-burden conditions that have been underdiagnosed, undertreated, or insufficiently funded despite clear epidemiological need across reproductive, maternal, oncologic, cardiometabolic, autoimmune, pelvic, menopausal, and mental health categories.

Organizations that align clinical evidence, AI governance, patient access, and regional market realities can improve outcomes while building defensible healthcare positions. Women's health is no longer a niche category; it is a core pillar of resilient, inclusive healthcare systems and a critical pathway to better population health outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Women's Health Market, by Product

• 7.1. Medical Devices
  • 7.1.1. Contraceptive Devices
  • 7.1.2. Diagnostic Tools
  • 7.1.3. Pregnancy Monitoring Devices
• 7.2. Pharmaceuticals
  • 7.2.1. Fertility Medications
  • 7.2.2. Hormonal Drugs
  • 7.2.3. Pain Management
• 7.3. Supplements & Nutraceuticals
  • 7.3.1. Bone Health
  • 7.3.2. Prenatal & Postnatal Vitamins

8. Women's Health Market, by Application

• 8.1. Fertility Enhancement
• 8.2. Gynecological Procedures
• 8.3. Hormonal Imbalance Treatment
• 8.4. Menstrual Disorder Management
• 8.5. Reproductive Health

9. Women's Health Market, by Distribution Channel

• 9.1. Offline
  • 9.1.1. Direct Sales
  • 9.1.2. Hospital Pharmacies
  • 9.1.3. Retail Pharmacies
• 9.2. Online
  • 9.2.1. E-Commerce Platforms
  • 9.2.2. Online Pharmacies

10. Women's Health Market, by End User

• 10.1. Clinics
• 10.2. Homecare Settings
• 10.3. Hospitals

11. Women's Health Market, by Age Group

• 11.1. Adolescents (10-19)
• 11.2. Reproductive Age (20-40)
• 11.3. Perimenopause (40-50)
• 11.4. Postmenopause (50+)

12. Women's Health Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Women's Health Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Women's Health Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. AbbVie Inc.
• 16.3. Amgen Inc.
• 16.4. Aspira Women's Health
• 16.5. Ava Women
• 16.6. Bayer AG
• 16.7. CooperCompanies, Inc.
• 16.8. Dare Bioscience
• 16.9. Eli Lilly and Company
• 16.10. Endo International plc
• 16.11. Everlywell
• 16.12. Evofem Biosciences, Inc. by Aditxt, Inc.
• 16.13. Ferring Holding SA
• 16.14. Flo Health
• 16.15. Gedeon Richter Plc
• 16.16. Hologic, Inc.
• 16.17. Johnson & Johnson
• 16.18. Mayne Pharma Group Limited
• 16.19. Medtronic PLC
• 16.20. Merck & Co., Inc.
• 16.21. Myovant Sciences Ltd. by Sumitomo Pharma Co., Ltd.
• 16.22. Organon & Co.
• 16.23. Pfizer Inc.
• 16.24. Pomelo Care, Inc.
• 16.25. Radius Health, Inc.
• 16.26. Roche Holding AG
• 16.27. Syneos Health
• 16.28. Theramex HQ UK Limited
• 16.29. TherapeuticsMD, Inc.
• 16.30. Zambon S.p.A.